Company profile
Biohaven Ltd. logo

Biohaven Ltd.

Pipeline11 assets

  • Taldefgrobep AlfaBHV-2000 / myostatin/activin receptor signaling / recombinant protein; myostatin-activin pathway inhibitor / neuromuscular; metabolic
    Spinal muscular atrophyPhase 3ObesityPhase 1
  • OpakalimBHV-7000 / Kv7.2/Kv7.3 potassium channels / small molecule Kv7 activator / neurology; psychiatry
    Focal epilepsyPhase 3Generalized epilepsyPhase 3Major depressive disorderPhase 2
  • TRPM3 AntagonistBHV-2100 / TRPM3 / oral small molecule antagonist / pain
    Pain disordersPhase 2
  • TYK2/JAK1 InhibitorBHV-8000 / TYK2/JAK1 / brain-penetrant small molecule inhibitor / neuroinflammation
    Parkinson's diseasePhase 3Prevention of amyloid therapy induced ARIAPhase 1Alzheimer's diseasePhase 1
  • IgG DegraderBHV-1300 / IgG / MoDE extracellular protein degrader / immunology
    Graves' disease / rheumatoid arthritisPhase 1
  • IgG DegraderBHV-1310 / IgG / MoDE extracellular protein degrader / immunology
    Myasthenia gravisPreclinical
  • Gd-IgA1 TRAP DegraderBHV-1400 / galactose-deficient IgA1 / TRAP extracellular protein degrader / immunology; renal
    IgA nephropathyPhase 1
  • β1AR Autoantibody DegraderBHV-1600 / β1AR autoantibodies / bifunctional MoDE degrader / cardiovascular
    Peripartum cardiomyopathyPhase 1
  • Trop2 ADC +/- PD1BHV-1510 / TROP2 / antibody-drug conjugate / oncology
    Advanced or metastatic epithelial tumorsPhase 1
  • FGFR3 ADCBHV-1530 / FGFR3 / antibody-drug conjugate / oncology
    Urothelial cancer and other tumorsPhase 1
  • CD30 ADCBHV-1500 / CD30 / antibody-drug conjugate / oncology
    Hodgkin lymphomaPreclinical

Latest news9 items

All news

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

BHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TSHR-IgG1exceeding >80% over the 12-week study. Participants with Graves' overt hyperthyroidism,

Interim Data • Phase 1R&D and Analyst Day presentation Wed, May 27, 2026, 7:30 AM EDT

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a generalized tonic-clonic seizure was 141 days in the opakalim 75 mg once-daily treatment group vs. 47 days in the placebo group, representing a 3-fold

Presentation / Abstract • Phase 2/3R&D Day presentation Wed, May 27, 2026, 7:30 AM EDT

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale University . Early clinical experience in patients

Presentation / Abstract

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective response rates 3/5 (60%) in NSCLC, 4/4 (100%) in endometrial cancer, and 1/2 (50%) in urothelial cancer

Presentation / Abstract • Phase 1